A new mixed-backbone oligonucleotide against glucosylceramide synthase sensitizes multidrug-resistant tumors to apoptosis.

A new mixed-backbone oligonucleotide against glucosylceramide synthase sensitizes multidrug-resistant tumors to apoptosis.

Enhanced ceramide glycosylation catalyzed by glucosylceramide synthase (GCS) limits therapeutic efficiencies of antineoplastic agents including doxorubicin in drug-resistant cancer cells. Aimed to determine the role of GCS in tumor response to chemotherapy, a new mixed-backbone oligonucleotide (MBO-...

Full description

Bibliographic Details
Main Authors: Gauri A Patwardhan, Qian-Jin Zhang, Dongmei Yin, Vineet Gupta, Jianxiong Bao, Can E Senkal, Besim Ogretmen, Myles C Cabot, Girish V Shah, Paul W Sylvester, S Michal Jazwinski, Yong-Yu Liu
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2009-09-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC2735002?pdf=render

Internet

http://europepmc.org/articles/PMC2735002?pdf=render

Similar Items